Evotec company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

evotec.com

Founded Year

1993

Stage

Corporate Minority - P2P | IPO

Market Cap

4.94B

About Evotec

Evotec (FWB: EVT) is a biotechnology company engaged in the discovery and development of small-molecule drugs. The company specializes in the area of Central Nervous System (CNS) related diseases where it is building a pipeline of drug candidates for partnering.

Evotec Headquarter Location

Essener Bogen 7

Hamburg, 22419,

Germany

+49 (0)40 560 81-0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Evotec Patents

Evotec has filed 33 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Pyridines
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/29/2016

11/12/2019

Clusters of differentiation, Immune system, Immunology, Transcription factors, Cytokines

Grant

Application Date

2/29/2016

Grant Date

11/12/2019

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Cytokines

Status

Grant

Latest Evotec News

EVOTEC : Buy rating from Deutsche Bank

Aug 12, 2022

(marketscreener.com) In his latest research note, analyst Falko Friedrichs confirms his positive recommendation. The broker Deutsche Bank is keeping its Buy rating. The target price is unchanged and still at EUR 30.https://www.marketscreener.com/quote/stock/EVOTEC-SE-436047/news/EVOTEC-Buy-rating-from-Deutsche-Bank-41295057/?utm_medium=RSS&utm_content=20220812

Evotec Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Evotec Rank

  • When was Evotec founded?

    Evotec was founded in 1993.

  • Where is Evotec's headquarters?

    Evotec's headquarters is located at Essener Bogen 7, Hamburg.

  • What is Evotec's latest funding round?

    Evotec's latest funding round is Corporate Minority - P2P.

  • Who are the investors of Evotec?

    Investors of Evotec include Bristol-Myers Squibb, Novo Holdings, Mubadala Investment Company and Gimv.

  • Who are Evotec's competitors?

    Competitors of Evotec include Arena Pharmaceuticals, Integral Molecular, Radyus, Embera NeuroTherapeutics, Ardelyx, Arctoris, Oxford BioTherapeutics, Hydra Biosciences, Actinobac Biomed, Auspex Pharmaceuticals and 24 more.

You May Also Like

C
Cenes

The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Integral Molecular Logo
Integral Molecular

Integral Molecular develops technologies to enable the discovery and development of drugs that target integral membrane proteins, which are involved directly or indirectly in most major diseases, and comprise nearly half of all existing drug targets, including G protein-coupled receptors (GPCRs) and ion channels.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

X
Xytis

Xytis is engaged in the development of central nervous systems drugs.

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

F
Functional Genetics

FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.